Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Raw Materials (2017 - 2023)

Historic Raw Materials for Perspective Therapeutics (CATX) over the last 11 years, with Q3 2023 value amounting to $764000.0.

  • Perspective Therapeutics' Raw Materials fell 1622.81% to $764000.0 in Q3 2023 from the same period last year, while for Sep 2023 it was $764000.0, marking a year-over-year decrease of 1622.81%. This contributed to the annual value of $752000.0 for FY2022, which is N/A changed from last year.
  • According to the latest figures from Q3 2023, Perspective Therapeutics' Raw Materials is $764000.0, which was down 1622.81% from $781000.0 recorded in Q2 2023.
  • In the past 5 years, Perspective Therapeutics' Raw Materials ranged from a high of $912000.0 in Q3 2022 and a low of $330000.0 during Q3 2019
  • Moreover, its 5-year median value for Raw Materials was $645000.0 (2021), whereas its average is $598105.3.
  • In the last 5 years, Perspective Therapeutics' Raw Materials surged by 9868.77% in 2021 and then tumbled by 1622.81% in 2023.
  • Quarter analysis of 5 years shows Perspective Therapeutics' Raw Materials stood at $372000.0 in 2019, then rose by 20.43% to $448000.0 in 2020, then surged by 67.63% to $751000.0 in 2021, then grew by 0.13% to $752000.0 in 2022, then rose by 1.6% to $764000.0 in 2023.
  • Its last three reported values are $764000.0 in Q3 2023, $781000.0 for Q2 2023, and $777000.0 during Q1 2023.